In 2000, Dr. Michael Nitsche and Dr. Walter Paulus launched conventional transcranial Direct Current Stimulation by showing lasting changes in brain plasticity. To date, over 100 clinical trials have investigated the ‘plasticity-boosting’ effects tDCS for the treatment of neuro-psychiatric diseases and as an adjunct to rehabilitation. Soterix Medical announces the completion of trial by Dr. Nitsche and Dr. Paulus comparing plasticity produced by conventional tDCS and High-Definition tDCS. Results show that HD-tDCS produces larger excitability and longer lasting changes. 10 minutes of HD-tDCS produced over 2 hours of lasting plasticity changes, with less average skin sensation than conventional tDCS, and no significant side-effects.View the paper here
“We could not be more pleased with these results. High-Definition tDCS combines the true neuromodulation of tDCS with the focality of TMS” Dr. Abishek Datta, CTO of Soterix Medical Inc. explains. "With this land-mark study by the leaders in low-intensity neuromodulation, we now know that HD-tDCS can produce longer lasting plasticity changes than tDCS or TMS. The implications of ‘peak’ neuroplasticity in clinical treatment, where long lasting changes are critical are clear.”
For more on Soterix Medical HD-tDCS
Media Contact
Narges Ghazi
Email: contact@soterixmedical.com
At Soterix Medical Inc., Engineering Serving Humanity means that we're committed to bring the most advanced medical technology into the hands of people who need it. The commitment underpins everything we do.
